The University will use the SOPHiA DDM™ Platform to enhance blood cancer testing and research
Boston, MA and Rolle, Switzerland, January 31, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Medicinski fakultet Univerziteta u Beogradu is live on the SOPHiA DDM™ Platform. The University, which is located in the capital city of Serbia, will use SOPHiA GENETICS’ technology, particularly the hematology-oncology application, to support the enhanced and accurate analysis of lymphoid neoplasms, which are the most common type of blood cancer affecting more than 100,000 people.
Medicinski fakultet Univerziteta u Beogradu is a hallmark of Serbia that has served patients in the region for more than 100 years. The higher education institution carries out scientific research in a variety of specialty areas, including hematology-oncology. By using the SOPHiA DDM™ Platform, Medicinski fakultet Univerziteta u Beogradu can ensure fast and accurate genomic analysis, and maximum discovery of variants associated with blood cancers.
“Advances in the study of cancers and other diseases depend on timely, cost-effective, and reliable sequencing strategies,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. “The implementation of the SOPHiA DDM™ Platform will help the Medicinski fakultet Univerziteta u Beogradu save time and valuable resources while quickly producing reliable insights from its testing.”
The SOPHiA DDM™ Platform is a customizable solution that uses next-generation sequencing to target key variants from FFPE, blood, or bone marrow samples helping lead to better detection of variants associated with the disease. The Platform is specifically designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect genomic variants associated with rare and challenging cases. Additionally, the SOPHiA DDM™ Platform has NGS-based workflows that help ensure Medicinski fakultet Univerziteta u Beogradu can quickly obtain biologically actionable insights from each sample to support data-driven decision-making.
The SOPHiA DDM™ Platform delivers results that are nearly 100 percent reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA DDM™ for Lymphoid Malignancies is available as a CE-IVD product for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
[email protected]
